https://www.immedica.com/endaily1.0 https://www.immedica.com/en/multiple-myeloma2023-04-04T14:03Znever https://www.immedica.com/en/media2024-04-12T06:48Zyearly https://www.immedica.com/en/press-releases2024-04-12T06:49Zyearly https://www.immedica.com/en/image-bank2024-04-12T06:49Zyearly https://www.immedica.com/en/calendar2024-04-12T06:50Zyearly https://www.immedica.com/en/subscribe2024-04-12T06:50Zyearly https://www.immedica.com/en/management-team2024-04-12T06:44Zyearly https://www.immedica.com/en/strategy-and-business-model2024-04-12T06:42Zyearly https://www.immedica.com/en/organisation2024-04-12T06:34Zyearly https://www.immedica.com/en/vision-and-values2024-04-12T06:43Zyearly https://www.immedica.com/en/ceo-statement2024-04-12T06:42Zyearly https://www.immedica.com/en/therapeutic-areas2026-03-19T10:47Zweekly https://www.immedica.com/en/genetic-metabolic-diseases2024-04-12T06:45Zyearly https://www.immedica.com/en/hematology-oncology2024-04-12T06:46Zyearly https://www.immedica.com/en/specialty-care2024-04-12T06:45Zyearly https://www.immedica.com/en/sustainability2025-03-17T15:58Zyearly https://www.immedica.com/en/governance2023-04-25T10:56Znever https://www.immedica.com/en/sustainability-report2024-04-26T11:22Zyearly https://www.immedica.com/en/transparency2026-03-23T15:31Zweekly https://www.immedica.com/en/contact2024-04-12T06:51Zyearly https://www.immedica.com/en/partnership2024-04-12T06:57Zyearly https://www.immedica.com/en/stories2024-04-12T06:53Zyearly https://www.immedica.com/en/careers2025-09-19T12:08Zyearly https://www.immedica.com/en/stories/rare-challenge-living-urea-cycle-disorder2025-02-18T13:24Zyearly https://www.immedica.com/en/stories/how-ensure-medical-supply-global-crisis2024-04-12T07:54Zyearly https://www.immedica.com/en/stories/patient-safety-core-our-business2024-04-12T07:53Zyearly https://www.immedica.com/en/stories/do-you-want-career-rare-diseases2024-04-12T07:54Zyearly https://www.immedica.com/en/headquarter-contact2024-04-12T06:51Zyearly https://www.immedica.com/en/local-contacts2024-04-12T06:52Zyearly https://www.immedica.com/en/ordering2024-04-12T06:52Zyearly https://www.immedica.com/en/safety-and-product-complaints2024-04-12T06:52Zyearly https://www.immedica.com/en/press/positive-results-pivotal-phase-3-sierra-trial-patients-relapsed-or-refractory-acute-myeloid2023-03-14T12:37Znever https://www.immedica.com/en/press/helsinn-and-immedica-enter-exclusive-partnership-commercialization-cancer-supportive-care2023-03-14T12:37Znever https://www.immedica.com/en/calendar/ebmt-annual-meeting-20232023-05-03T13:24Znever https://www.immedica.com/en/reporting-misconducts2024-04-12T06:47Zyearly https://www.immedica.com/en/stories/immedica-way-managing-manufacturing2024-04-12T07:54Zyearly https://www.immedica.com/en/stories/we-can-do-better-rare-diseases-nordics2024-04-12T07:54Zyearly https://www.immedica.com/en/stories/immedica-and-china2024-04-12T07:55Zyearly https://www.immedica.com/en/stories/three-factors-consider-when-working-rare-diseases2024-04-12T07:55Zyearly https://www.immedica.com/en/stories/immedica-shares-know-how-and-expertise-individuals-urea-cycle-disorders2024-04-12T07:55Zyearly https://www.immedica.com/en/stories/one-thing-you-need-understand-setting-pharma-business-cee-central-eastern-europe2024-04-12T07:55Zyearly https://www.immedica.com/en/stories/doing-business-middle-east-and-north-africa2024-04-12T07:56Zyearly https://www.immedica.com/en/stories/learn-how-handle-bumpy-road-urea-cycle-disorder2024-04-12T07:56Zyearly https://www.immedica.com/en/stories/meet-mark-bell2024-04-12T07:56Zyearly https://www.immedica.com/en/press/ravictir-glycerol-phenylbutyrate-approved-department-health-hongkong-treatment-urea-cycle2023-04-13T12:04Znever https://www.immedica.com/en/press/top-line-results-phase-3-sierra-trial-iomab-b-announced-21102532023-04-13T12:04Znever https://www.immedica.com/en/press/strong-growth-and-recruitments-required-more-office-space-21102642023-04-13T12:04Znever https://www.immedica.com/en/press/nmpa-grants-priority-review-nda-glycerol-phenylbutyrate-21102652023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-welcomes-linda-holmstrom-head-communication-21102742023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-pharma-and-innovative-medicines-announces-anmat-and-invima-filing-acceptance2023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-pharma-ab-submits-marketing-authorisation-application-european-medicines-agency2023-04-13T12:04Znever https://www.immedica.com/en/press/zepzelcar-lurbinectedin-has-received-innovation-passport-innovative-medicine-designation-mhra2023-04-13T12:04Znever https://www.immedica.com/en/press/zepzelcatm-lurbinectedin-approved-qatar-treatment-metastatic-small-cell-lung-cancer-sclc2023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-and-orphanpacific-enter-agreement-giving-orphanpacific-rights-ravictir-glycerol2023-04-13T12:04Znever https://www.immedica.com/en/press/actinium-pharmaceuticals-inc-and-immedica-announce-commercialization-agreement-iomab-b-131i2023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-welcomes-heidi-ramstad-new-chief-medical-officer-21105032023-04-13T12:04Znever https://www.immedica.com/en/press/achievement-primary-endpoint-phase-3-study-pegzilarginase-patients-arginase-1-deficiency2023-04-13T12:04Znever https://www.immedica.com/en/press/zepzelcatm-lurbinectedin-approved-united-arab-emirates-uae-treatment-metastatic-small-cell2023-04-13T12:04Znever https://www.immedica.com/en/press/aeglea-biotherapeutics-and-immedica-announce-commercialization-agreement-pegzilarginase2023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-acquires-rights-additional-ophthalmology-products-european-countries-21108882023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-and-winhealth-enter-agreement-giving-winhealth-rights-ravictir-china-and-several2023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-acquires-rights-ravictir-and-buphenylr-japan-horizon-therapeutics-plc-21109032023-04-13T12:04Znever https://www.immedica.com/en/press/pharmamar-signs-agreement-immedica-21113492023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-speaker-nordic-american-life-science-conference-2019-new-york-city-21113722023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-starts-distribute-ravictir-and-ammonapsr-europe-and-middle-east-1-january-20202023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-acquires-rights-ophthalmology-products-european-countries-21115482023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-expands-its-management-team-simon-falk-joins-immedica-cfo-21115712023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-pharma-becomes-market-authorisation-holder-ammonapsr-and-ravictir-europe-21115742023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-acquires-rights-ravictir-and-ammonapsr-outside-north-america-and-japan-21115782023-04-13T12:04Znever https://www.immedica.com/en/press/we-medical-need-and-immedica-group-are-moving-21115792023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-gains-right-anti-tumor-agent-yondelisrin-united-kingdom-21115802023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-expands-its-management-team-nina-fleck-and-hakan-garpenstrand-joins-immedica-21115842023-04-13T12:04Znever https://www.immedica.com/en/press/immedica-platform-pan-european-niche-specialty-pharma-launch-commercialization-and2023-04-13T12:04Znever https://www.immedica.com/en/rare-diseases2024-04-12T06:34Zyearly https://www.immedica.com/en/gdpr2024-04-12T06:59Zyearly https://www.immedica.com/en/terms-use2024-04-12T06:58Zyearly https://www.immedica.com/en/code-conduct2025-09-03T15:13Zyearly https://www.immedica.com/en/cookie-notice2024-04-12T06:58Zyearly https://www.immedica.com/en/commitment-make-difference-patients-lives2024-04-12T06:47Zyearly https://www.immedica.com/en/sustainable-organization-and-operations2024-08-15T11:24Zyearly https://www.immedica.com/en/press/immedicas-partner-orphanpacific-initiates-phase-3-trial-glycerol-phenylbutyrate-treatment2023-04-25T06:09Znever https://www.immedica.com/en/stories/sevim-hasozbek2024-04-12T07:52Zyearly https://www.immedica.com/en/stories/umang-vakharia2024-04-12T07:53Zyearly https://www.immedica.com/en/medical-information-contacts2024-04-12T06:51Zyearly https://www.immedica.com/en/calendar/epns-15th-epns-congress2023-05-03T13:24Znever https://www.immedica.com/en/calendar/ssiem-2023-ssiem-annual-symposium2023-05-03T13:25Znever https://www.immedica.com/en/press/immedica-publishes-business-review-and-annual-sustainability-report-2022-21188992023-05-17T12:30Znever https://www.immedica.com/en/press/iomab-b-sierra-trial-results-accepted-oral-presentation-european-hematology-association-20232023-05-15T09:20Znever https://www.immedica.com/en/report/immedica-publishes-business-review-and-annual-sustainability-report-20222023-05-17T12:31Znever https://www.immedica.com/en/calendar/bio-international-convention2023-06-01T11:38Znever https://www.immedica.com/en/calendar/european-hematology-association2023-06-01T11:29Znever https://www.immedica.com/en/calendar/european-association-nuclear-medicine2023-06-01T11:33Znever https://www.immedica.com/en/calendar/european-society-blood-and-marrow-transplantation2023-06-01T11:37Znever https://www.immedica.com/en/stories/annika-envall2024-04-12T07:52Zyearly https://www.immedica.com/en/press/glycerol-phenylbutyrate-approved-national-medical-products-administration-china-treatment2023-06-21T05:30Znever https://www.immedica.com/en/press/zepzelcar-lurbinectedin-approved-ministry-health-oman-treatment-metastatic-small-cell-lung2023-07-21T11:15Znever https://www.immedica.com/en/press/immedica-acquires-global-rights-pegzilarginase-aeglea-21469112023-07-27T11:05Znever https://www.immedica.com/en/press/i131-apamistamab-sierra-abstracts-accepted-oral-and-poster-presentation-european-association2023-08-25T06:00Znever https://www.immedica.com/en/press/immedica-present-new-pegzilarginase-data-ssiem-annual-symposium-2023-21534762023-08-29T03:12Znever https://www.immedica.com/en/stories/what-urea-cycle-disorder2024-04-12T07:51Zyearly https://www.immedica.com/en/stories/arginase-1-deficiency2024-04-12T07:53Zyearly https://www.immedica.com/en/press/ravictir-glycerol-phenylbutyrate-approved-national-administration-drugs-food-and-medical2023-09-29T07:30Znever https://www.immedica.com/en/calendar/european-society-medical-oncology-esmo-congress2023-10-03T15:33Znever https://www.immedica.com/en/calendar/afsos-french-oncology-supportive-care-association2023-10-03T15:39Znever https://www.immedica.com/en/calendar/tao-ctm-cancer-toxicity-management-meeting2023-10-03T15:46Znever https://www.immedica.com/en/press/loargysr-pegzilarginase-receives-positive-opinion-chmp-treatment-arginase-1-deficiency2023-10-13T11:40Znever https://www.immedica.com/en/press/glycerol-phenylbutyrate-granted-orphan-drug-designation-treatment-stxbp1-developmental-and2023-10-20T08:00Znever https://www.immedica.com/en/calendar/cphi-20232023-10-20T08:57Znever https://www.immedica.com/en/calendar/bio-europe2023-10-24T07:47Znever https://www.immedica.com/en/calendar/jpm-healthcare-conference2023-10-24T13:37Znever https://www.immedica.com/en/calendar/jefferies-healthcare-conference2023-10-24T13:40Znever https://www.immedica.com/en/stories/ali-and-poppy2025-02-18T13:25Zyearly https://www.immedica.com/en/press/immedicas-partner-actinium-announces-oral-presentation-ash-annual-meeting-iomab-b-outcomes2023-11-14T13:30Znever https://www.immedica.com/en/stories/development-within-rare-diseases-prof-marshall-summar2024-04-12T07:51Zyearly https://www.immedica.com/en/press-release-japanese2023-12-19T06:56Znever https://www.immedica.com/en/press-release-chinese2023-12-19T06:56Znever https://www.immedica.com/en/press/loargysr-pegzilarginase-approved-eu-treatment-arginase-1-deficiency-arg1-d-21850532023-12-18T14:15Znever https://www.immedica.com/en/stories/challenges-within-rare-diseases-prof-marshall-summar2024-04-12T07:50Zyearly https://www.immedica.com/en/stories/we-are-immedica2024-04-12T07:50Zyearly https://www.immedica.com/en/press/immedica-intends-re-submit-bla-seeking-approval-loargysr-pegzilarginase-treatment-arginase-12023-12-21T10:00Znever https://www.immedica.com/en/press/loargysr-pegzilarginase-approved-great-britain-treatment-arginase-1-deficiency-arg1-d-21865032023-12-22T09:15Znever https://www.immedica.com/en/nor-noha2024-01-11T12:45Znever https://www.immedica.com/en/stories/importance-collaborations-within-rare-diseases2024-04-12T07:50Zyearly https://www.immedica.com/en/press-release-portuguese2024-02-26T07:15Znever https://www.immedica.com/en/press/immedicas-partner-actinium-presented-four-abstracts-iomab-b-2024-tandem-meetings2024-02-27T07:00Znever https://www.immedica.com/en/press/anonymity-recognition-challenge-underdiagnosis-and-misdiagnosis-rare-diseases-22084922024-02-29T07:00Znever https://www.immedica.com/en/calendar/aps-annual-conference-and-seminar-20242024-03-12T09:38Znever https://www.immedica.com/en/calendar/ssiem-annual-symposium-20242024-03-12T09:44Znever https://www.immedica.com/en/calendar/international-child-neurology-congress2024-03-12T09:49Znever https://www.immedica.com/en/calendar/27e-rencontres-infirmieres-en-oncologie-rio2024-03-12T09:58Znever https://www.immedica.com/en/calendar/masccafsosisoo-2024-annual-meeting2024-03-12T10:02Znever https://www.immedica.com/en/stories/role-pharma-industry-within-rare-diseases-02024-03-19T09:32Znever https://www.immedica.com/en/stories/what-arginase-1-deficiency2024-03-19T10:28Znever https://www.immedica.com/en/stories/what-urea-cycle-disorder-ucd2024-03-19T14:52Znever https://www.immedica.com/en/press/ravictir-glycerol-phenylbutyrate-approved-taiwan-food-and-drug-administration-tfda-treatment2024-03-21T11:15Znever https://www.immedica.com/en/press/immedicas-partner-actinium-announces-iomab-b-phase-3-sierra-trial-results-patients-tp532024-04-18T08:15Zyearly https://www.immedica.com/en/press/immedica-recognized-one-swedens-best-workplaces-2024-great-place-workr-22232432024-04-19T07:40Zyearly https://www.immedica.com/en/press/leading-global-investment-firm-kkr-and-nordic-healthcare-investment-firm-impilo-enters2024-04-23T05:15Zyearly https://www.immedica.com/en/sustainability-report-archive2024-04-30T07:41Zyearly https://www.immedica.com/en/press/immedica-announces-publication-2023-business-review-and-annual-sustainability-report-22264222024-04-26T11:15Zyearly https://www.immedica.com/en/annual-report-archive2024-04-30T07:45Zyearly https://www.immedica.com/en/multi-language-press-releases2024-06-18T11:15Zyearly https://www.immedica.com/en/press/immedicas-partner-actinium-announces-iomab-b-phase-3-sierra-trial-results-patients-tp53-02024-06-15T15:30Zyearly https://www.immedica.com/en/press/immedica-presents-new-data-highlighting-treatment-benefits-loargysr-pegzilarginase-arginase-12024-09-03T09:00Zyearly https://www.immedica.com/en/press/immedica-expands-us-establishes-chicago-based-commercial-business-22628812024-09-09T10:00Zyearly https://www.immedica.com/en/press/immedica-appoints-daniel-camardo-president-immedica-north-america-22646492024-09-17T11:00Zyearly https://www.immedica.com/en/press/immedica-initiates-phase-3-pediatric-study-loargysr-pegzilarginase-arginase-1-deficiency2024-09-18T12:45Zyearly https://www.immedica.com/en/press/joint-acquisition-immedica-pharma-completed-22654962024-09-20T06:00Zyearly https://www.immedica.com/en/press/joe-whalen-joins-immedicas-business-development-team-22662252024-09-24T07:45Zyearly https://www.immedica.com/en/press/immedica-publishes-key-study-societal-impact-arg1-d-22666282024-10-02T08:40Zyearly https://www.immedica.com/en/press/data-phase-3-sierra-trial-iomab-b-presented-annual-european-association-nuclear-medicine-eanm2024-10-25T09:30Zyearly https://www.immedica.com/en/press/bla-pegzilarginase-treatment-arginase-1-deficiency-arg1-d-accepted-priority-review-us-fda2024-11-05T16:00Zyearly https://www.immedica.com/en/press/immedica-welcomes-benjamin-owens-head-corporate-development-22789102024-11-11T08:40Zyearly https://www.immedica.com/en/press/application-ministry-health-japan-ravictir-glycerol-phenylbutyrate-submitted-22903182024-12-27T08:30Zyearly https://www.immedica.com/en/press/immedica-acquire-biopharmaceutical-company-marinus-pharmaceuticals-inc-22905772024-12-30T12:00Zyearly https://www.immedica.com/en/calendar/jp-morgan-health-care-conference2025-01-07T13:24Zyearly https://www.immedica.com/en/press/immedica-commence-tender-offer-all-outstanding-shares-common-stock-marinus-pharmaceuticals2025-01-08T21:05Zyearly https://www.immedica.com/en/calendar/bio-international-convention-20252025-01-20T14:14Zyearly https://www.immedica.com/en/calendar/european-academy-childhood-disabilities2025-01-21T09:08Zyearly https://www.immedica.com/en/calendar/epns-european-paediatric-neurology-society-congress2025-01-21T09:10Zyearly https://www.immedica.com/en/calendar/iciem-international-congress-inborn-errors-metabolism2025-01-21T09:12Zyearly https://www.immedica.com/en/press/immedica-successfully-completes-tender-offer-all-outstanding-shares-common-stock-marinus2025-02-07T11:35Zyearly https://www.immedica.com/en/press/immedica-completes-acquisition-marinus-pharmaceuticals-inc-22997082025-02-11T13:35Zyearly https://www.immedica.com/en/stories/brie-and-vanessa-sharing-life-arginase-1-deficiency2025-06-10T11:24Zyearly https://www.immedica.com/en/rare-neurology2025-03-10T15:10Zyearly https://www.immedica.com/en/calendar/european-lung-cancer-congress2025-03-17T15:21Zyearly https://www.immedica.com/en/calendar/bio-europe-spring2025-03-17T15:32Zyearly https://www.immedica.com/en/calendar/2025-asco-annual-meeting2025-03-17T15:28Zyearly https://www.immedica.com/en/press/immedica-strengthens-focus-rare-diseases-new-therapeutic-area-23189732025-04-10T09:32Zyearly https://www.immedica.com/en/press/immedica-ranked-top-2-among-swedens-best-workplacestm-2025-23233632025-04-25T08:00Zyearly https://www.immedica.com/en/expanded-access-statement-us2025-05-06T14:43Zyearly https://www.immedica.com/en/press/immedica-publishes-annual-sustainability-report-2024-23299512025-05-13T13:12Zyearly https://www.immedica.com/en/stories/living-arginase-1-deficiency-rare-metabolic-disorder2025-06-10T11:14Zyearly https://www.immedica.com/en/press/immedica-mah-ztalmyr-ganaxolone-eu-23389742025-06-12T08:00Zyearly https://www.immedica.com/en/press/immedica-regains-commercial-rights-mena-region-ztalmyr-ganaxolone-23401422025-06-17T12:00Zyearly https://www.immedica.com/en/press/ovid-therapeutics-enters-agreement-immedica-pharma-ab-sale-future-ganaxolone-royalties2025-06-25T12:02Zyearly https://www.immedica.com/en/press/ravictir-glycerol-phenylbutyrate-approved-saudi-arabia-qatar-and-kuwait-23821262025-08-18T10:00Zyearly https://www.immedica.com/en/press/immedica-publishes-favorable-long-term-data-loargysr-pegzilarginase-23866532025-08-29T08:00Zyearly https://www.immedica.com/en/press/immedica-and-innovative-medicines-group-enter-agreement-loargysr-pegzilarginase-latin-america2025-10-01T09:00Zyearly https://www.immedica.com/en/optimizing-tolerability-ganaxolone-treatment-rare-seizure-disorders-using-modified-titration2025-10-25T03:04Zyearly https://www.immedica.com/en/press/immedica-submits-new-drug-submission-nds-loargysr-pegzilarginase-health-canada-24020562025-10-31T11:00Zyearly https://www.immedica.com/en/modified-titration-regimen-ganaxolone-treatment-rare-seizure-disorders-optimizes-tolerability2025-11-14T15:50Zyearly https://www.immedica.com/en/phase-i-single-dose-study-ganaxolone-pharmacokinetics-adult-subjects-normal-and-impaired-hepatic2025-11-14T15:51Zyearly https://www.immedica.com/en/press/zepzelcar-lurbinectedin-combination-atezolizumab-approved-first-line-maintenance-therapy2025-11-28T13:33Zyearly https://www.immedica.com/en/press/immedica-submits-pegzilarginase-application-australian-therapeutic-goods-administration-tga2025-12-09T16:00Zyearly https://www.immedica.com/en/press/loargysr-pegzilarginase-granted-marketing-authorization-oman-treatment-arginase-1-deficiency2025-12-10T09:00Zyearly https://www.immedica.com/en/stories/day-life-alix-bessonnet2025-12-19T09:43Zyearly https://www.immedica.com/en/press/immedica-and-orphanpacific-announce-approval-ravictir-glycerol-phenylbutyrate-japan-treatment2025-12-22T17:05Zyearly https://www.immedica.com/en/press/immedica-acquire-neurocrine-group-limited-neurocrine-biosciences-european-rare-commercial2026-01-08T17:00Zyearly https://www.immedica.com/en/press/immedica-announces-fda-acceptance-pegzilarginase-bla-resubmission-us-24181802026-01-14T14:00Zyearly https://www.immedica.com/en/press/immedica-completes-acquisition-neurocrine-group-limited-neurocrine-biosciences-european-rare2026-01-21T14:45Zyearly https://www.immedica.com/en/press/immedica-announces-positive-results-phase-3-study-loargysr-pegzilarginase-patients-below-22026-02-02T13:01Zyearly https://www.immedica.com/en/press/us-fda-has-granted-accelerated-approval-loargysr-pegzilarginase-nbln-treatment2026-02-23T19:10Zmonthly https://www.immedica.com/en/stories/alices-story-living-arginase-1-deficiency2026-02-25T14:09Zmonthly https://www.immedica.com/en/press/ravictir-glycerol-phenylbutyrate-approved-united-arab-emirates-and-sultanate-oman-24317542026-03-04T08:30Zmonthly https://www.immedica.com/en/rare-endocrinology2026-03-19T10:41Zweekly https://www.immedica.com/en/press/zepzelcar-lurbinectedin-combination-atezolizumab-receives-positive-chmp-opinion-first-line2026-03-27T13:30Zweekly https://www.immedica.com/en/press/immedica-announces-first-marketing-authorization-approval-mena-region-ztalmyr-ganaxolone2026-04-01T11:20Zhourly https://www.immedica.com/en/home2026-03-19T10:43Zmonthly1.0 https://www.immedica.com/en/about-us2024-04-12T06:33Zyearly https://www.immedica.com/en/board2024-04-12T06:41Zyearly https://www.immedica.com/en/products2026-03-19T10:37Zweekly https://www.immedica.com/en/ucd2023-04-04T14:05Znever